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Abstract
Introduction: Changes in sex hormones with weight loss might have implications for breast cancer prevention but
have not been examined extensively, particularly in African-American (AA) women.
Methods: We conducted a prospective study of 278 overweight/obese postmenopausal women (38% AA) not
taking hormone therapy within the Weight Loss Maintenance Trial. All participants lost at least 4 kg after a
6-month weight-loss phase and attempted to maintain weight loss during the subsequent 12 months. We
evaluated the percentage changes in estrone, estradiol, free estradiol, testosterone, free testosterone,
androstenedione, dehydroepiandrosterone sulfate and sex hormone-binding globulin (SHBG) using generalized
estimating equations.
Results: In all study phases, AA women had higher levels of estrogen and testosterone concentrations,
independent of adiposity. On average, participants lost 7.7 kg during the weight-loss phase, and concentrations of
estrone (-5.7%, P = 0.006), estradiol (-9.9%, P <0.001), free estradiol (-13.4%, P <0.0001), and free testosterone (-9.9%,
P <0.0001) decreased, while the SHBG concentration (16.2%, P <0.001) increased. Weight change did not
significantly affect total testosterone or other androgen concentrations. Compared with non-AA women, AA
women experienced less change in estrogens per kilogram of weight change (that is, per 1 kg weight loss:
estrone, -0.6% vs. -1.2%, P-interaction = 0.10; estradiol, -1.1% vs. -1.9%, P-interaction = 0.04; SHBG, 0.9% vs. 1.6%,
P-interaction = 0.006; free estradiol, -1.4% vs. -2.1%, P-interaction = 0.01).
Conclusion: To the best of our knowledge this is the first study to examine and compare the effects of intentional
weight loss and maintenance on a panel of sex hormones in AA women and non-AA women. Although
speculative, these data suggest hormonal differences may contribute to different racial patterns of breast cancer
incidence and mortality and encourage further investigations to understand the long-term effects of weight loss
on sex hormones in obese postmenopausal women.
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Introduction
Over the past several decades, the prevalence of obesity
has increased in the United States [1]. Nearly 70% of
postmenopausal women are overweight or obese [1].
These women experience a 30 to 50% greater risk of
breast cancer compared with leaner women [2]. The
International Agency for Research on Cancer estimates
that 25% of breast cancer cases may be attributable to
obesity and sedentary lifestyle [2]. These associations
may be due to alterations in endogenous hormones,
including bioavailable sex steroids [3].
Obesity is linked to higher levels of circulating sex
steroid hormone concentrations in postmenopausal
women not taking hormone replacement [4], but studies
examining the long-term effects of intentional weight
reduction on endogenous sex hormones are surprisingly
limited. Most studies have been small with durations <6
months [5-19]. For the majority of studies, weight loss
was the consequence of a low-fat diet or an exercise
intervention [5-19]. To the best of our knowledge, only
one recent adequately powered clinical trial has exam-
ined the direct effects of weight loss on sex hormones
[20] and none have examined weight loss maintenance.
Additionally, none of these studies have included a sub-
stantial number of African-American (AA) women, a
population that has a greater prevalence of obesity [21],
unique incidence patterns of hormone-receptor-defined
breast cancer subtypes [22], and higher breast cancer
mortality when compared with Caucasian women. A
better understanding of the long-term effects of weight
loss on endogenous sex hormones in obese postmeno-
pausal women may provide clues to the racial differ-
ences in breast cancer incidence and prognosis, and
might have major implications for prevention.
We conducted a study among postmenopausal women
participants of the Weight Loss Maintenance Trial
(WLM) [23] who were overweight or obese at study
entry and not taking hormone replacement. The objec-
tive of our study was to determine the effects of weight
loss and maintenance of weight loss on sex hormone
concentrations, overall and by race (AA and non-AA).
Materials and methods
Weight Loss Maintenance Trial
A detailed description of the WLM is published elsewhere
[23,24]. The WLM (clinicaltrials.gov NCT00054925) was a
multicenter, randomized trial of 1,032 men and women
with the primary aim to test the effects of two interven-
tions compared with an advice-only control group for
maintaining initial weight loss. The primary outcome of
the trial was weight.
The trial had two phases. Phase 1 was a nonrando-
mized 6-month group-based intensive behavioral weight
loss intervention of 1,685 participants led by a trained
interventionist that promoted reducing caloric intake
and increasing physical activity (to at least 180 minutes/
week) to lose 1 to 2 pounds per week [23]. Participants
were encouraged to follow the Dietary Approaches to
Stop Hypertension diet, which is high in fiber and low
in fat content [25]. Major inclusion criteria for participa-
tion in phase 1 were: body mass index (BMI) between
25 and 45 kg/m2; current medication use for hyperten-
sion, dyslipidemia, or both; access to a telephone and to
the Internet; and ability to keep a food diary for 5 days
during the screening. Major exclusion criteria were
medication-treated diabetes mellitus, a recent cardiovas-
cular event or other medical or psychiatric condition
that would preclude full participation in the study,
weight loss >9 kg during the last 3 months, recent use
of weight loss medications and prior weight loss surgery
or scheduled surgery for this purpose [24].
Those who lost at least 4 kg in phase 1 were eligible
for phase 2 of the WLM, a three-arm trial in which
1,032 individuals were randomized into one of two
weight-maintenance interventions or a minimal care,
self-directed/usual care control group [23]. The two
interventions were a Personal Contact intervention that
provided monthly personal contacts by a trained inter-
ventionist primarily via telephone, or an Interactive
Technology intervention that provided unlimited con-
tacts through an interactive Web-based program supple-
mented by other communication technologies [23]. The
duration of phase 2 was 30 months.
Recruitment for the 6-month intensive behavioral
weight loss program, phase 1 occurred between August
2003 and July 2004 [23]. Those who completed phase 1
and qualified for phase 2 were randomized from Febru-
ary through December 2004 to one of the three inter-
vention groups [23]. Data collection was completed in
June 2007 [23].
The study was approved by an institutional review
board at each of four participating clinical sites, by the
study’s coordinating center, by a protocol review com-
mittee appointed by the National Heart, Lung, and
Blood Institute, and by the Office of Human Subjects
Research at the National Institutes of Health. Partici-
pants provided an informed consent for phase 1 and
phase 2.
Data collection
For our analyses, we used data collected at three points:
study entry; 6 months later at the end of phase 1, which
was the point of randomization into phase 2; and 12
months after randomization [23]. Height was measured
using a calibrated, wall-mounted stadiometer at entry.
Weight was measured in duplicate according to the
WLM protocol using a high-quality, calibrated digital
scale by trained staff members who were masked to
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treatment assignment [23]. At the end of the weight loss
intervention and 12 months later, weight was measured
on two separate days and values were averaged. Diet
was assessed using a self-administered Block Food Fre-
quency Questionnaire (NutritionQuest, Berkeley, CA.
USA). Physical activity was measured using a calibrated,
triaxial accelerometer (RT3; Stayhealthy Inc, Monrovia,
CA, USA) for ≥10 hoursper/day for at least 4 days,
including one weekend day. Accelerometry measures
were used to calculate weekly minutes of moderate to
vigorous physical activity. Participants self-reported their
race.
Identification of postmenopausal women
We administered a questionnaire to all female participants
during the weight loss program to determine menopausal
status. Menopause was defined as no menstrual periods
during the last 12 months and/or surgical removal of both
ovaries. Women older than 60 years were considered post-
menopausal. For women between the ages of 48 and 60
years we confirmed menopausal status by considering
levels of follicular stimulating hormone and estradiol from
blood samples. Hormone replacement use was determined
from questions that ascertain medications during the
scheduled data collection. Among the 654 female partici-
pants in the trial, we identified from the questionnaire 313
postmenopausal participants who were not taking hor-
mone replacement therapy at any time during the trial.
From these participants, we further excluded 35 women,
including 29 with high levels of total estradiol (>50 pg/ml,
an indication that they were taking estrogen therapy or
were not menopausal) and six with low follicular stimulat-
ing hormone (<30 mIU/ml, suggesting not menopausal).
In total, 278 postmenopausal women were included in our
analyses.
Collection of blood samples and laboratory analysis of
sex hormones
We collected 2 ml serum samples from the study partici-
pants after an overnight fast at three time points: prior to
the weight loss intervention (phase 1 entry), 6 months
later (the end of phase 1 and randomization into phase 2),
and at 12 months after randomization (also 18 months
after entry). The blood samples were processed, then sent
to and stored at -70°C at the WLM biorepository, and
transferred to the National Cancer Institute biorepository
prior to laboratory measures. The three serum samples
collected from the same participant were analyzed conse-
cutively as triplets within each batch to minimize the
laboratory variation between samples from the same
subject.
The stored serum samples were shipped on dry ice to
Dr Frank Stanczyk’s laboratory at University Southern
California Keck School of Medicine, where estrone,
estradiol, testosterone, androstenedione, dehydroepian-
drosterone sulfate (DHEAS) and sex hormone-binding
globulin (SHBG) were measured in 2008. Estrone, total
estradiol, testosterone and androstenedione were mea-
sured by validated radioimmunoassays after organic
solvent extraction and Celite column partition chroma-
tography [26,27]. DHEAS and SHBG were measured by
direct immunoassays using the Immulite analyzer (Diag-
nostic Products Corporation, Inglewood, CA, USA). Free
estradiol and free testosterone concentrations were cal-
culated from measured estradiol, total testosterone, and
SHBG with albumin assumed to be a constant (40 g/l)
using the method by Sodergard and colleagues accord-
ing to the law of mass action [28]. The lowest concen-
tration of detection for estradiol was 3 pg/ml. Estradiol
values below the detection limits were assigned a value
of 3 pg/ml. There were three women at baseline, six
women after the weight loss intervention at randomiza-
tion, and 10 women at the 12-month weight loss main-
tenance phase that had estradiol concentrations below
the detection limits (values <3 pg/ml). We also included
10% blinded quality control samples (n = 94) from two
pools of serum composed from thin and overweight/
obese postmenopausal women not taking hormone
replacement therapy. Duplicate blinded quality control
samples were placed in each batch. Using a nested com-
ponents of variance analysis, with logarithmically trans-
formed quality control measurements across all batches
[29], the estimated overall (intrabatch and interbatch)
coefficients of variation for estrone, estradiol, testoster-
one, androstenedione, DHEAS, and SHBG were 20%,
4.3%, 10%, 10%, 8.4%, and 4.3%, respectively.
Statistical analysis
We analyzed the effect of weight loss and weight loss
maintenance on hormone concentration as a prospective
cohort without regard to treatment, since all participants
in our study lost at least 4 kg and we assumed that
changes in hormone concentrations are mediated through
weight regardless of randomization to the weight mainte-
nance interventions. To investigate the effect of weight
loss on the logarithm of each hormone, we fit separate
marginal regression models using generalized estimating
equations with an independence working correlation
matrix to estimate robust standard errors that accounted
for multiple measurements over time within a subject.
These models estimated the mean, and the percentage
change in, hormone concentrations over each study phase.
All models were adjusted for race, age, enrollment BMI,
physical activity, and phase. Other variables examined as
potential confounders included education, smoking his-
tory, alcohol use, energy, total and saturated fat and carbo-
hydrate intake, dyslipidemia medication use, history of
oopherectomy, endogenous hormones, and SHBG.
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We used generalized estimating equations models to
test whether hormone levels differ by race, adjusted for
BMI at each time (0, 6 and 18 months), using chi-square
tests on three degrees of freedom (Figure 1). Modification
of the effect of weight change by race, trial intervention,
enrollment BMI, age, physical activity, and dyslipidemia
medication were assessed by stratifying the models on
levels of each factor and testing whether the weight
change coefficients were equal with t tests. For the analy-
sis of the modification of the effect of weight change by
race and enrollment BMI, we additionally combined data
over the study phase because the phase did not modify
the effect of weight.
Results
The mean age at study entry was 59.3 years (range 46 to
78 years), 37.8% were AA, 90% were postmenopausal for
at least 2 years at the start of the trial, and 40% were tak-
ing dyslipidemia medication (Table 1). Compared with
the non-AA women, the AA women were more likely to
have a higher BMI and severe obesity (BMI >35 kg/m2),
had a surgical menopause, had lower income, and pre-
sented less dyslipidemia medication use (Table 1).
Overall, participants averaged a 7.7 kg weight loss by
the end of the weight loss phase (entry vs. 6 months),
with significant reductions in estrone (-5.7%), estradiol
(-9.9%), free estradiol (-13.4%), and free testosterone
(-9.9%) concentrations, and an increase in SHBG (16.2%)
concentrations (Table 2, columns 5 and 6). During the
weight maintenance phase overall (6 months vs. 18
months), body weight increased 2.2 kg on average while
estrone (-6.4%) and SHBG (-8.0%) decreased and free tes-
tosterone (5.0%) increased; otherwise, there were no
other significant changes (Table 2, columns 7 and 8). The
total testosterone and other androgens (androstenedione
and DHEAS) did not significantly change, except that
among the women with stage 2 obesity (BMI >35 kg/m2)
testosterone decreased (-6.0%, P = 0.04) after the initial
weight loss (average -8.3 kg) and increased (8.2%, P =
0.02) during the weight maintenance phase with an aver-
age weight gain of 2.3 kg. After the initial weight loss,
those who gained weight had significant decreases in
Figure 1 Hormone concentrations by race in the Weight Loss Maintenance Trial, United States, 2003-2005 . Estrone, estradiol,
testosterone, and sex hormone binding globulin (SHBG) concentration by race in the Weight Loss Maintenance Trial, United States, 2003-2005.
Mean hormone concentrations during weight loss and weight maintenance within race groups, and 95% confidence intervals from generalized
estimating equations adjusted for age, physical activity, phase, and body mass index (kg/m2) at each time (0, 6, and 18 months). P values from a
chi-square test on three degrees of freedom.
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SHBG (-14.5%) and consequently increases in free estra-
diol (9.0%) and free testosterone (10.4%), but no change
in other hormone concentrations (Table 3). Those who
maintained their weight loss did not have significant
changes in sex hormones except for a slight decrease in
SHBG (-5.3%). Those who continued to lose weight had
further significant reductions in the level of estrone
(-5.2%) and increases in androstenedione (8.8%).
Table 1 Baseline characteristics of postmenopausal women not taking hormones, Weight Loss Maintenance Trial
Characteristic Overall (n = 278) African-American (n = 105) Non-African-American (n = 173)
Age (years) 46 to 78 47 to 73 46 to 78




Native American 1 (0.36%)
Asian 1 (0.36%)
Body mass index (kg/m2) 33.4 (4.9) 34.3 (4.6) 32.9 (4.9)
World Health Organization category
Overweight: 25 to 30 kg/m2 83 (29.9%) 22 (21.0%) 61(35.3%)
Obesity
Stage 1: 30 to 34.9 kg/m2 98 (35.3%) 38 (36.2%) 60 (34.7%)
Stage 2: ≥35 kg/m2 97 (34.9%) 45 (42.9%) 52 (30.1%)
Physical activity (MVPA/week) 91.7 (86.1) 82.0 (69.9) 97.3 (93.9)
Alcohol (g) 4.3 (8.1) 2.1 (4.1) 5.6 (9.5)
Years since periods stoppeda
≤4 years 62 (22.30%) 20 (19.05%) 42 (24.28%)
5 to 9 years 39 (14.03%) 15 (14.29%) 24 (13.87%)
10 to 19 years 77 (27.70%) 31 (29.52%) 46 (26.59%)
20 years 46 (16.55%) 16 (15.24%) 30 (17.34%)
Reason periods stopped
Natural menopause 163 (58.6%) 53(50.5%) 110 (63.6%)
Surgery (uterus and/or ovaries removed) 100 (36.0%) 48(45.7%) 52(30.1%)
Bilateral oopherectomy 51(18.3%) 20 (19.0%) 31 (17.9%)
Other 15 (5.4%) 4 (3.8%) 11(6.4%)
Age periods stopped (years)
<45 years 83 (29.9%) 40 (38.1%) 43 (24.9%)
45 to 49 years 55 (19.8%) 21 (20.0%) 34 (19.7%)
50 to 52 years 56 (20.1%) 18 (17.1%) 38 (22.0%)
>53 years 81 (29.1%) 25 (23.8%) 56 (32.4%)
Age of menarche (years)a
≤11 years 138 (49.6%) 50 (48.5%) 88 (50.9%)
12 to 13 years 83 (29.9%) 26 (24.8%) 57 (32.9%)
>14 years 54 (19.4%) 28 (26.7%) 26 (15.0%)
Education
College degree 157 (56.48%) 58 (55.24%) 99 (57.23%)
Household income
≥$60,000 111 (39.93%) 38 (36.19%) 73 (42.20%)
Smoker
Never 160 (57.55%) 60 (57.14%) 100 (57.80%)
Former 105 (37.77%) 40 (38.10%) 65 (37.57%)
Current 13 (4.68%) 5 (4.76%) 8 (4.62%)
Dyslipidemia medication use 111 (39.93%) 31 (29.52%) 80 (46.24%)
Statin use 102 (36.69%) 29 (27.62%) 73 (42.20%)
Data presented as range, mean (standard deviation) or n (%). MVPA, moderate to vigorous physical activity. aProportions do not add to 100% due to missing
data: years after menopause, n = 54; race, n = 1 refused; education, n = 3; household income, n = 20; age of menarche, n = 3.
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Combining data from both phases (Table 4), a 1 kg
weight loss was associated with a 1.0% decrease and a
1.6% decrease in estrone and estradiol, respectively, a
1.3% increase in SHBG (P <0.0001), and consequently a
1.9% decrease and a 0.8% decrease in free estradiol and
free testosterone, respectively, with no change in other
androgen concentrations. However, the magnitude of
these changes differed between AA women and non-AA
women. Compared with non-AA women, AA women
experienced less change in hormone per kilogram of
weight lost, with estrone declining 0.6% versus 1.2% (P-
interaction = 0.10), estradiol declining 1.1% versus 1.9%
(P-interaction = 0.04), and free estradiol declining 1.4%
versus 2.1% (P-interaction = 0.01), while SHBG
increased less (0.9% vs. 1.6%, P-interaction = 0.006).
Total testosterone and other androgen concentrations
were unaffected by weight change for both races. On
average, AA women experienced slightly less decrease in
weight (-7.1 vs. -8.0 kg) and BMI (-2.7 vs. -3.0 kg/m2)
after the intervention but a similar increase in weight
(2.2 kg) and BMI (0.9 kg/m2) during weight mainte-
nance. AA women also had higher circulating estrogen
and testosterone concentrations compared with non-AA
women (Figure 1), after controlling for BMI during all
study phases.
Exclusion of women who reported recent menopause
and who might have higher estrogen concentrations (<4
years ago), have had bilateral oophorectomy (n = 51
women), or have nonmedicated diabetes did not sub-
stantially alter our results (data not shown). There were
no significant interactions for the effect of weight
change by enrollment BMI category, trial intervention
(Tables S1, S2, S3 in Additional file 1), age, physical
activity, or dyslipidemia medication use (data not
shown).
Discussion
To the best of our knowledge this is the first study to
examine the consequence of intentional weight loss and
weight loss maintenance on a panel of sex hormones in
AA women and also compare the effects with those for
non-AA women. In our study of overweight and obese
postmenopausal women, intentional weight loss signifi-
cantly reduced serum concentrations of estrone, estra-
diol, free estradiol and free testosterone, and increased
SHBG, but had no effect on total testosterone and other
androgen concentrations. The effect of weight loss dif-
fered by race, with AA women experiencing less change
in estrone, estradiol, free estradiol, and SHBG per kilo-
gram change than non-AA women. In addition, AA
women had higher estrogen and testosterone concentra-
tions, independent of adiposity. Sustaining the weight
loss for the subsequent 12 months did not substantially
change sex hormone concentrations except for slight
increases in SHBG. For those who continued to lose
weight during the weight maintenance phase, estrone
continued to decrease.
One aspect of our study is that 38% of our population
was AA. The AA women have higher mortality rates than
non-AA women despite a lower overall incidence of breast
cancer [22], and present with more aggressive disease dis-
tinguished by higher grade, poorer survival, and estrogen
receptor (ER)-negative status [22,30]. Compared with non-
AA women, the AA women in our study had higher con-
centrations of estrone, estradiol, and testosterone that were
independent of BMI across all study phases and an
Table 2 Hormone change during weight loss and maintenance among postmenopausal women not taking hormones















Initial 6 months 18 months % Δ P value % Δ P value
Weight (kg)a 89.1 (14.8) 81.4 (14.4) 83.6 (15.6) -7.7 <0.0001 2.2 <0.0001
Hormone
Estrone (pg/ml) 38.1 (1.1) 35.9 (1.0) 33.6 (1.0) -5.7 0.006 -6.4 0.003
Estradiol (pg/ml) 9.4 (0.3) 8.4 (0.3) 8.5 (0.3) -9.9 <0.0001 0.5 0.85
Testosterone (ng/ml) 24.6 (0.9) 23.7 (0.8) 24.0 (0.8) -3.5 0.13 1.1 0.62
Androstenedione (pg/ml) 437 (12.1) 434 (11.9) 438 (12.9) -0.5 0.76 0.8 0.68
Dehydroepiandrosterone sulfate (µg/dl) 47.0 (1.8) 47.8 (1.8) 46.6 (1.9) 1.7 0.31 -2.5 0.18
Sex hormone binding globulin (nmol/l) 35 (1.0) 40 (1.0) 37 (1.0) 16.2 <0.0001 -8.0 <0.0001
Free estradiol (pg/ml) 0.26 (0.01) 0.22 (0.01) 0.23 (0.01) -13.4 <0.0001 3.7 0.18
Free testosterone (pg/ml) 5.3 (0.2) 4.8 (0.2) 5.1 (0.2) -9.9 <0.0001 5.0 0.02
n = 278. Generalized estimating equations models used to estimate the mean (standard error) and percentage change (% Δ) in hormone concentrations over
each study phase adjusted for age, physical activity, phase, initial body mass index (kg/m2), and race. aRow represents the mean (standard deviation) for weight
at the start of each phase, average weight change between each phase and overall.
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attenuated change in estrogen concentrations with weight
loss. These observations are consistent with the few recent
cross-sectional studies demonstrating for AA women that
circulating estrogens are higher than for non-AA women in
both premenopausal and postmenopausal women [31-34].
While the ovaries are the primary source of estrogens
in premenopausal women, estrogen synthesis also occurs
in the adipose tissue [35]. Obesity and/or adult weight
gain increase postmenopausal breast cancer risk in Cau-
casian women, particularly for ER-positive disease. The
evidence for AA women, however, is equivocal [36],
with positive, null, and inverse associations reported
[30,36,37]. The reasons for these differences are unclear.
Although speculative, the higher absolute levels and
smaller change in estrogen concentrations in response
to weight loss that we observe among AA women may
provide a clue. There is experimental evidence that high
levels of circulating estrogens promote the formation
and progression of ER-negative breast tumors through a
systemic increase in angiogenesis rather than by binding
to the hormone receptor [35]. ER-negative breast cancer
may also evolve from estrogen-responsive progenitor
cells that lose their sensitivity to estrogens later in the
carcinogenesis process [38].
Moreover, mammary stem cells have been shown to
respond to sex hormone signaling, despite having an
Table 3 Hormone changes during weight maintenance phase, stratified by changes in weight criteria
Months since study entry Effect of weight change on hormones
End of weight loss phase Weight loss maintenance 6 months vs. 18 months
6 months 18 months % Δ P value
Weight gain >3% (n = 141)
Weight (kg)a 82.2 (13.8) 87.6 (14.77) 5.4 <0.0001
Hormone
Estrone (pg/ml) 35.6 (1.6) 34.8 (1.5) -2.2 0.50
Estradiol (pg/ml) 8.4 (0.4) 8.8 (0.4) 4.2 0.20
Testosterone (ng/dl) 21.5 (1.1) 22.1 (1.1) 2.7 0.36
Androstenedione (pg/ml) 417 (17.1) 406 (18.1) -2.9 0.34
Dehydroepiandrosterone sulfate (µg/dl) 48.6 (2.8) 47.6 (2.9) -2.0 0.34
Sex hormone binding globulin (nmol/l) 38.2 (1.3) 32.6 (1.1) -14.5 <0.0001
Free estradiol (pg/ml) 0.22 (0.01) 0.24 (0.01) 9.0 0.006
Free testosterone (pg/ml) 4.5 (0.2) 4.9 (0.3) 10.4 0.0007
Weight maintainers, ≤3% weight gain (n = 68)
Weight (kg)a 82.6 (15.2) 84.0 (15.5) 1.4 <0.0001
Hormone
Estrone (pg/ml) 37.2 (1.9) 35.3 (1.9) -5.2 0.17
Estradiol (pg/ml) 9.4 (0.7) 9.2 (0.6) -2.3 0.55
Testosterone (ng/dl) 27.1 (1.9) 26.4 (1.7) -2.6 0.59
Androstenedione (pg/ml) 473 (22.0) 475 (22.2) 0.4 0.92
Dehydroepiandrosterone sulfate (µg/dl) 50.1 (3.6) 47.3 (3.4) -5.6 0.16
Sex hormone binding globulin (nmol/l) 39.1 (2.1) 37.0 (1.9) -5.3 0.01
Free estradiol (pg/ml) 0.25 (0.02) 0.25 (0.02) -1.1 0.78
Free testosterone (pg/ml) 5.6 (0.4) 5.6 (0.4) -0.2 0.97
Continued weight loss (n = 69)
Weight (kg)a 78.5 (14.6) 75.2 (14.0) -3.4 <0.0001
Hormone
Estrone (pg/ml) 37.0 (2.0) 31.4 (1.9) -15.2 0.0003
Estradiol (pg/ml) 8.3 (0.6) 8.0 (0.7) -3.8 0.60
Testosterone (ng/dl) 25.7 (1.6) 26.2(1.8) 2.1 0.55
Androstenedione (pg/ml) 434 (25.6) 472 (28.7) 8.8 0.02
Dehydroepiandrosterone sulfate (µg/dl) 44.4 (3.0) 44.4 (3.6) -0.02 1.00
Sex hormone binding globulin (nmol/l) 47.4 (2.9) 48.3 (2.9) 1.9 0.48
Free estradiol (pg/ml) 0.21 (0.02) 0.2 (0.02) -1.5 0.84
Free testosterone (pg/ml) 4.7 (0.3) 4.8 (0.3) 1.2 0.70
Generalized estimating equations models used to estimate mean (standard error) and percentage change (% Δ) in hormone concentrations over each study
phase adjusted for race, age, physical activity, phase and initial body mass index (kg/m2). aRow represents the mean (standard deviation) for weight at the start
of each phase, average weight change between each phase and overall.
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ER-negative phenotype [39]. This concept is indirectly
supported epidemiologically by the transient increased
incidence of breast cancer, particularly ER-negative
tumors, that occurs after a full-term pregnancy, when
estrogen concentrations are at their highest [35].
Further, parity is associated with higher rates of triple-
negative disease in both Caucasian and AA women
[40,41]. It is plausible that AA women have inherently
higher estrogen concentrations compared with Cauca-
sians, which contributes to the distinctive negative
receptor phenotype of breast cancer in AA women that
is independent of adiposity. The endogenous sex hor-
mone differences could also contribute to the greater
bone density observed among AA women [42,43], or,
more broadly, the higher incidence of other hormone-
related cancers among AA people [44]. A genetic com-
ponent, such as genes related to steroid hormone meta-
bolism, may perhaps explain the nature of breast tumor
biology in women of African descent more strongly
than adiposity [22].
Our results are consistent with a recent 12-month ran-
domized controlled trial of postmenopausal women (the
Nutrition and Exercise for Women trial) that examined
the effects of caloric restriction, exercise, or both on sex
hormone concentrations compared with those of a con-
trol group [20]. Both studies showed that weight loss as a
result of caloric restriction and exercise significantly
decreases estrogens and free testosterone, and increases
SHBG with less striking reductions in total testosterone
[20] and no significant changes in the other androgens
[20]. Although exercise trials in sedentary, overweight or
obese postmenopausal women have not shown consistent
overall effects of exercise on sex hormone concentra-
tions, they do suggest reductions in estradiol [15,45],
testosterone [46,47], and androstenedione [47], and
increases in SHBG [15], among women who experienced
concomitant weight loss [15] and/or changes in body
composition, specifically fat distribution [45-47].
Compared with these previous trials, our study had
slightly more obese participants, none of whom had a
normal weight prior to enrollment, and a higher propor-
tion of AA women. In addition, our study was of longer
duration with the goal to maintain lost weight for the
subsequent year. The weight loss achieved by the WLM
participants during the first 6 months was comparable
with that of the caloric-restricted Nutrition and Exercise
for Women trial participants, with and without physical
activity, and substantially more than that of participants
in the exercise trials. Higher compared with lower blood
estrogen and testosterone concentrations have been asso-
ciated with breast cancer risk in multiple prospective stu-
dies [48-53]. The Endogenous Hormone and Breast
Cancer Collaborative Group showed in a pooled analysis
that the significant positive association between BMI and
postmenopausal breast cancer was reduced after adjust-
ment for estrogens, particularly bioavailable estradiol,
and SHBG, whereas adjustment for the androgens did
not substantially change the BMI association [4]. Our
results and those of others support the hypothesis that
intentional weight loss might reduce the risk of breast
cancer by decreasing estrogens more so than androgens
[4,20].
Our findings are consistent with the known inter-
relationship of obesity, physical activity, insulin, sex hor-
mones and SHBG [54-56]. The decreases in estrogens
we observed in overweight and obese postmenopausal
women with sustained weight loss may be explained by
declines in intra-abdominal body fat, which is the predo-
minant site for estrogen production in postmenopausal
women [54,55]. Weight loss also improves insulin sensi-
tivity and the resulting lowered insulin levels enhance
hepatic synthesis of SHBG [54], the protein that
Table 4 Change in hormone level per kilogram weight change over 18 months, overall and by race





% Δ/kg P value % Δ/kg P value % Δ/kg P value
Estrone (pg/ml) 1.0 <0.0001 0.6 0.03 1.2 <0.0001 0.10
Estradiol (pg/ml) 1.6 <0.0001 1.1 <0.0001 1.9 <0.0001 0.04
Testosterone (ng/dl) 0.2 0.22 -0.02 0.95 0.3 0.15 0.30
Androstenedione (pg/ml) -0.2 0.19 -0.2 0.44 -0.2 0.18 1.0
Dehydroepiandrosterone sulfate (μg/dl) 0.4 0.07 0.5 0.14 0.2 0.36 0.5
Sex hormone binding globulin (nmol/l) -1.3 <0.0001 -0.9 <0.0001 -1.6 <0.0001 0.006
Free estradiol (pg/ml) 1.9 <0.0001 1.4 <0.0001 2.1 <0.0001 0.01
Free testosterone (pg/ml) 0.8 <0.0001 0.5 0.05 1.0 <0.0001 0.07
Generalized estimating equations models using the combined data across all phases of the logarithm of each hormone regressed on weight (kg) adjusted for
race, age, physical activity, and phase. For example, overall estradiol increases 1.6% per kilogram of weight gain or decreases 1.6% per kilogram of weight loss. In
African Americans, losing 1 kg means estradiol decreases 1.1% or gaining 1 kg means estradiol increases 1.1%; while in non-African Americans, losing or gaining
1 kg means estradiol decreases 1.9% or increases 1.9% respectively. The interaction or differences in percentage change (% Δ) in estradiol concentration by race
is statistically significant (P-interaction = 0.04).
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effectively binds both estradiol and testosterone, thereby
limiting the amount of bioavailable steroid hormone in
circulation [54]. Estrone is the predominant hormone
present in postmenopausal women and is synthesized
from androstenedione via aromatase in adipose tissue.
The significant decrease in estrone concentrations
among the women who continued to lose weight during
the maintenance phase may possibly be in response to
the sustained loss of adipose tissue. The lack of a signifi-
cant change in SHBG within this group might be
explained by a threshold effect related to maintaining
the improved insulin sensitivity and lower insulin levels
that occurred after the original weight loss.
The strengths of our study are the prospective design,
the relatively large sample size with repeated measures of
hormones on the same women over 18 months, and the
valid and reliable measures of estrogens and androgens.
We were also able to evaluate the effects on hormones of
initial weight loss, as well as weight loss maintenance,
weight regain, and continued weight loss. We avoid hor-
mone replacement masking changes in endogenous sex
hormones related to weight change because none of the
women in our study were taking hormone replacement.
Weight was measured in a standard manner by trained
staff [23].
There are also limitations to the study. Our study only
included overweight or obese women who successfully
lost weight. The differences we observed in hormone
concentrations between AA women and non-AA women
might be explained by the slightly higher BMI of AA
women compared with non-AA women in our study
(Table 2); however, the fact that there was no significant
interaction of the hormone changes by enrollment BMI
category in our study (Tables S1, S2 in Additional file 1)
would oppose this assertion. Although there was only a
small number of women with estradiol concentrations
below the detection limits, this could possibly influence
our estradiol results towards the null because the true
estradiol values are less than the values assigned. This
influence could explain why estrone continued to signifi-
cantly decrease with continued weight loss during the
maintenance phase while estradiol did not. Current med-
ication use for dyslipidemia was an inclusion criterion to
participate in the WLM study. While it is possible that
use of these medications could influence our results, they
did not confound or modify the changes in hormone
concentrations that we observed. We do not have infor-
mation on family history of breast cancer, parity, or mea-
sures of other hormones such as insulin or leptin that
might influence endogenous sex hormone concentra-
tions. The racial differences in SHBG response to weight
change might in part be explained by AA women having
higher insulin concentrations. Studies of longer duration
are needed to evaluate hormone changes associated with
substantial weight regain and cycling that occur fre-
quently among women. Finally, our study was not able to
relate weight loss to cancer outcomes.
Conclusion
Our results show that decreases in endogenous estrogens
persist following intentional weight loss that is main-
tained for at least 12 months but the magnitude differs
for AA women and non-AA women. Elevated levels of
sex steroid hormones have been proposed to mediate
many of the risk factors for postmenopausal breast can-
cer, including obesity, particularly for hormone receptor-
positive tumors. As the prevalence of obesity among
postmenopausal women increases worldwide, interven-
tion efforts to promote and maintain weight loss may
have a major public health impact for decreasing the bur-
den of breast cancer. The racial hormone differences that
we observe could have relevance to the distinctive tumor
phenotype and biology of breast cancer in AA women,
and possibly other hormone-related cancers in AA
women, which deserves further investigation.
Additional material
Additional file 1: Table S1 presenting sex hormone changes during
weight loss and weight loss maintenance within study entry BMI
category. Table S2 presenting the percentage change (% Δ) in hormone
concentration per kilogram of weight change: overall and by BMI at
study entry. Table S3 presenting weight and sex hormone changes
during weight loss and weight loss maintenance by weight loss
maintenance intervention.
Abbreviations
AA: African-American; BMI: body mass index; DHEAS:
dehydroepiandrosterone sulfate; ER: estrogen receptor; SHBG: sex hormone-
binding globulin; WLM: Weight Loss Maintenance Trial.
Acknowledgements
The authors acknowledge the contributions of all WLM investigators and
staff in conducting the parent WLM and thereby making this ancillary study
possible. They also acknowledge Dr Thomas Erlinger for his assistance with
the study concept and collecting the data, and Dr Sihui Zhao for his
assistance with the statistical analysis. This research was supported by the
Intramural Research Program of the National Institutes of Health, Division of
Cancer Epidemiology and Genetics, National Cancer Institute, Department of
Health and Human Services
Author details
1Division of Cancer Epidemiology and Genetics, National Cancer Institute,
National Institutes of Health, Department of Health and Human Services,
6120 Executive Boulevard, Rockville, MD 20854, USA. 2Reproductive
Endocrine Research Laboratory, Livingston Research Building, 1321 N.
Mission Road, Room 201, Los Angeles, CA 90033, USA. 3Welch Center for
Prevention, Epidemiology, and Clinical Research, Johns Hopkins Medical
Institutions, 2024 East Monument Street, Room 2-642, Baltimore, MD 21287,
USA. 4Epidemiology and Prevention, Maya Angelou Center for Health Equity,
Wake Forest University Baptist Medical Center, Medical Center Boulevard,
Winston Salem, NC 27157, USA. 5Division of Endocrinology, Metabolism and
Nutrition, Duke University Medical Center, 200 Trent Drive, Duke South
Orange Zone, DUMC Box 3031, Durham, NC 27710, USA. 6Department of
Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, 600
Stolzenberg-Solomon et al. Breast Cancer Research 2012, 14:R141
http://breast-cancer-research.com/content/14/5/R141
Page 9 of 11
N. Wolfe Street, Meyer 101, Baltimore MD 21287, USA. 7Division of
Endocrinology, Metabolism, and Nutrition, Sarah Stedman Nutrition and
Metabolism Center, Duke University Medical Center, Box 2956 DUHS, 201
Trent Drive, Durham, NC 27710, USA. 8Sarah W. Stedman Nutrition and
Metabolism Center, Duke Hypertension Center, 3475 Erwin Road, Suite 101D,
Durham, NC 27705, USA.
Authors’ contributions
RZS-S contributed to the concept of the study. RZS-S, RTF, and HAK
contributed to the study design, analysis, and interpretation of the results.
RZS-S and the Weight Loss Maintenance Collaborative Research Group (LJA,
JDA, LPS) contributed to the acquisition of the data. RZS-S, RTF, HAK, CP,
and XH contributed to the statistical analysis. RZS-S contributed to the
funding of the ancillary study of postmenopausal women, and LJA and LPS
to the WLM. FS measured the sex hormones. RZS-S drafted and revised the
manuscript. RTF, FS, RNH, LJA, JDA, BCB, JC, XH, LFL, CP, LPS, and HAK
provided substantive interpretation and editorial comments on manuscript
drafts. All authors reviewed and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 25 May 2012 Revised: 20 August 2012
Accepted: 24 September 2012 Published: 31 October 2012
References
1. Flegal KM, Carroll MD, Ogden CL, Curtin LR: Prevalence and trends in
obesity among US adults, 1999-2008. JAMA 2010, 303:235-241.
2. McTiernan A: Behavioral risk factors in breast cancer: can risk be
modified? Oncologist 2003, 8:326-334.
3. Cummings SR, Tice JA, Bauer S, Browner WS, Cuzick J, Ziv E, Vogel V,
Shepherd J, Vachon C, Smith-Bindman R, Kerlikowske K: Prevention of
breast cancer in postmenopausal women: approaches to estimating and
reducing risk. J Natl Cancer Inst 2009, 101:384-398.
4. Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C,
Stanczyk FZ, Stephenson HE, Falk RT, Miller R, Schatzkin A, Allen DS,
Fentiman IS, Key TJ, Wang DY, Dowsett M, Thomas HV, Hankinson SE,
Toniolo P, Akhmedkhanov A, Koenig K, Shore RE, Zeleniuch-Jacquotte A,
Berrino F, Muti P, Micheli A, Krogh V, Sieri S, Pala V, Venturelli E, et al: Body
mass index, serum sex hormones, and breast cancer risk in
postmenopausal women. J Natl Cancer Inst 2003, 95:1218-1226.
5. DeWaard F, Schwarz F: Weight reduction and postmenopausal estrogenic
effect. Acta Cytol 1964, 8:449-453.
6. Boyar AP, Rose DP, Loughridge JR, Engle A, Palgi A, Laakso K, Kinne D,
Wynder EL: Response to a diet low in total fat in women with
postmenopausal breast cancer: a pilot study. Nutr Cancer 1988, 11:93-99.
7. Prentice R, Thompson D, Clifford C, Gorbach S, Goldin B, Byar D: Dietary fat
reduction and plasma estradiol concentration in healthy
postmenopausal women. The Women’s Health Trial Study Group. J Natl
Cancer Inst 1990, 82:129-134.
8. Heber D, Ashley JM, Leaf DA, Barnard RJ: Reduction of serum estradiol in
postmenopausal women given free access to low-fat high-carbohydrate
diet. Nutrition 1991, 7:137-139.
9. Crighton IL, Dowsett M, Hunter M, Shaw C, Smith IE: The effect of a low-
fat diet on hormone levels in healthy pre- and postmenopausal women:
relevance for breast cancer. Eur J Cancer 1992, , 28A:: 2024-2027.
10. Rose DP, Connolly JM, Chlebowski RT, Buzzard IM, Wynder EL: The effects
of a low-fat dietary intervention and tamoxifen adjuvant therapy on the
serum estrogen and sex hormone-binding globulin concentrations of
postmenopausal breast cancer patients. Breast Cancer Res Treat 1993,
27:253-262.
11. Berrino F, Bellati C, Ooldani S, Mastroianni A, Allegro G, Berselli E,
Venturelli E, Cavalleri A, Cambie M, Pala V, Pasanisi P, Secreto G: DIANA
trials on diet and endogenous hormones. IARC Sci Publ 2002, 156:439-444.
12. Berrino F, Bellati C, Secreto G, Camerini E, Pala V, Panico S, Allegro G,
Kaaks R: Reducing bioavailable sex hormones through a comprehensive
change in diet: the diet and androgens (DIANA) randomized trial. Cancer
Epidemiol Biomarkers Prev 2001, 10:25-33.
13. Prentice RL, Caan B, Chlebowski RT, Patterson R, Kuller LH, Ockene JK,
Margolis KL, Limacher MC, Manson JE, Parker LM, Paskett E, Phillips L,
Robbins J, Rossouw JE, Sarto GE, Shikany JM, Stefanick ML, Thomson CA,
Van Horn L, Vitolins MZ, Wactawski-Wende J, Wallace RB, Wassertheil-
Smoller S, Whitlock E, Yano K, Adams-Campbell L, Anderson GL, Assaf AR,
Beresford SA, Black HR, Brunner RL, Brzyski RG, Ford L, Gass M, Hays J,
Heber D, Heiss G, Hendrix SL, Hsia J, Hubbell FA, Jackson RD, Johnson KC,
Kotchen JM, LaCroix AZ, Lane DS, Langer RD, Lasser NL, Henderson MM:
Low-fat dietary pattern and risk of invasive breast cancer: the Women’s
Health Initiative Randomized Controlled Dietary Modification Trial. JAMA
2006, 295:629-642.
14. Carty CL, Kooperberg C, Neuhouser ML, Tinker L, Howard B, Wactawski-
Wende J, Beresford SA, Snetselaar L, Vitolins M, Allison M, Budrys N,
Prentice R, Peters U: Low-fat dietary pattern and change in body-
composition traits in the Women’s Health Initiative Dietary Modification
Trial. Am J Clin Nutr 2011, 93:516-524.
15. Friedenreich CM, Woolcott CG, McTiernan A, Ballard-Barbash R, Brant RF,
Stanczyk FZ, Terry T, Boyd NF, Yaffe MJ, Irwin ML, Jones CA, Yasui Y,
Campbell KL, McNeely ML, Karvinen KH, Wang Q, Courneya KS: Alberta
physical activity and breast cancer prevention trial: sex hormone
changes in a year-long exercise intervention among postmenopausal
women. J Clin Oncol 2010, 28:1458-1466.
16. Tymchuk CN, Tessler SB, Barnard RJ: Changes in sex hormone-binding
globulin, insulin, and serum lipids in postmenopausal women on a low-
fat, high-fiber diet combined with exercise. Nutr Cancer 2000, 38:158-162.
17. Caballero MJ, Maynar M: Effects of physical exercise on sex hormone
binding globulin, high density lipoprotein cholesterol, total cholesterol
and triglycerides in postmenopausal women. Endocr Res 1992, 18:261-279.
18. Caballero MJ, Mahedero G, Hernandez R, Alvarez JL, Rodriguez J, Rodriguez I,
Maynar M: Effects of physical exercise on some parameters of bone
metabolism in postmenopausal women. Endocr Res 1996, 22:131-138.
19. Turcato E, Zamboni M, De Pergola G, Armellini F, Zivelonghi A, Bergamo-
Andreis IA, Giorgino R, Bosello O: Interrelationships between weight loss,
body fat distribution and sex hormones in pre- and postmenopausal
obese women. J Intern Med 1997, 241:363-372.
20. Campbell KL, Foster-Schubert KE, Alfano CM, Wang CC, Wang CY,
Duggan CR, Mason C, Imayama I, Kong A, Xiao L, Bain CE, Blackburn GL,
Stanczyk FZ, McTiernan A: Reduced-calorie dietary weight loss, exercise,
and sex hormones in postmenopausal women: randomized controlled
trial. J Clin Oncol 2012, 30:2314-2326.
21. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM:
Prevalence of overweight and obesity in the United States, 1999-2004.
JAMA 2006, 295:1549-1555.
22. Amend K, Hicks D, Ambrosone CB: Breast cancer in African-American
women: differences in tumor biology from European-American women.
Cancer Res 2006, 66:8327-8330.
23. Svetkey LP, Stevens VJ, Brantley PJ, Appel LJ, Hollis JF, Loria CM,
Vollmer WM, Gullion CM, Funk K, Smith P, Samuel-Hodge C, Myers V,
Lien LF, Laferriere D, Kennedy B, Jerome GJ, Heinith F, Harsha DW, Evans P,
Erlinger TP, Dalcin AT, Coughlin J, Charleston J, Champagne CM, Bauck A,
Ard JD, Aicher K: Comparison of strategies for sustaining weight loss: the
weight loss maintenance randomized controlled trial. JAMA 2008,
299:1139-1148.
24. Brantley P, Appel L, Hollis J, Stevens V, Ard J, Champagne C, Elmer P,
Harsha D, Myers V, Proschan M, William V, Svetkey L..: Design
considerations and rationale of a multi-center trial to sustain weight
loss: the Weight Loss Maintenance Trial. Clin Trials 2008, 5:546-556.
25. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM,
Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N: A clinical
trial of the effects of dietary patterns on blood pressure. DASH
Collaborative Research Group. N Engl J Med 1997, 336:1117-1124.
26. Stanczyk FZ, Lee JS, Santen RJ: Standardization of steroid hormone
assays: why, how, and when? Cancer Epidemiol Biomarkers Prev 2007,
16:1713-1719.
27. Ranadive GN, Mistry JS, Damodaran K, Khosravi MJ, Diamandi A, Gimpel T,
Castracane VD, Patel S, Stanczyk FZ: Rapid, convenient radioimmunoassay
of estrone sulfate. Clin Chem 1998, 44:244-249.
28. Sodergard R, Backstrom T, Shanbhag V, Carstensen H: Calculation of free
and bound fractions of testosterone and estradiol-17 beta to human
plasma proteins at body temperature. J Steroid Biochem 1982, 16:801-810.
29. Fears TR, Ziegler RG, Donaldson JL, Falk RT, Hoover RN, Stanczyk FZ,
Vaught JB, Gail MH: Reproducibility studies and interlaboratory
concordance for androgen assays in female plasma. Cancer Epidemiol
Biomarkers Prev 2000, 9:403-412.
Stolzenberg-Solomon et al. Breast Cancer Research 2012, 14:R141
http://breast-cancer-research.com/content/14/5/R141
Page 10 of 11
30. Agurs-Collins T, Dunn BK, Browne D, Johnson KA, Lubet R: Epidemiology of
health disparities in relation to the biology of estrogen receptor-
negative breast cancer. Semin Oncol 2010, 37:384-401.
31. Setiawan VW, Haiman CA, Stanczyk FZ, Le ML, Henderson BE: Racial/ethnic
differences in postmenopausal endogenous hormones: the multiethnic
cohort study. Cancer Epidemiol Biomarkers Prev 2006, 15:1849-1855.
32. Woods MN, Barnett JB, Spiegelman D, Trail N, Hertzmark E, Longcope C,
Gorbach SL: Hormone levels during dietary changes in premenopausal
African-American women. J Natl Cancer Inst 1996, 88:1369-1374.
33. Pinheiro SP, Holmes MD, Pollak MN, Barbieri RL, Hankinson SE: Racial
differences in premenopausal endogenous hormones. Cancer Epidemiol
Biomarkers Prev 2005, 14:2147-2153.
34. McTiernan A, Wu L, Barnabei VM, Chen C, Hendrix S, Modugno F, Rohan T,
Stanczyk FZ, Wang CY: Relation of demographic factors, menstrual
history, reproduction and medication use to sex hormone levels in
postmenopausal women. Breast Cancer Res Treat 2008, 108:217-231.
35. Gupta PB, Proia D, Cingoz O, Weremowicz J, Naber SP, Weinberg RA,
Kuperwasser C: Systemic stromal effects of estrogen promote the growth
of estrogen receptor-negative cancers. Cancer Res 2007, 67:2062-2071.
36. Rose DP, Haffner SM, Baillargeon J: Adiposity, the metabolic syndrome,
and breast cancer in African-American and white American women.
Endocr Rev 2007, 28:763-777.
37. Palmer JR, Adams-Campbell LL, Boggs DA, Wise LA, Rosenberg L: A
prospective study of body size and breast cancer in black women.
Cancer Epidemiol Biomarkers Prev 2007, 16:1795-1802.
38. Allred DC, Brown P, Medina D: The origins of estrogen receptor alpha-
positive and estrogen receptor alpha-negative human breast cancer.
Breast Cancer Res 2004, 6:240-245.
39. Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER,
Yasuda H, Smyth GK, Martin TJ, Lindeman GJ, Visvader JE: Control of
mammary stem cell function by steroid hormone signalling. Nature 2010,
465:798-802.
40. Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Wactawski-Wende J,
Kuller LH, Adams-Campbell LL, Lane D, Stefanick ML, Vitolins M, Kabat GC,
Rohan TE, Li CI. .: Reproductive history and oral contraceptive use in
relation to risk of triple-negative breast cancer. J Natl Cancer Inst 2011,
103:470-477.
41. Palmer JR, Boggs DA, Wise LA, Ambrosone CB, Adams-Campbell LL,
Rosenberg L: Parity and lactation in relation to estrogen receptor
negative breast cancer in African American women. Cancer Epidemiol
Biomarkers Prev 2011, 20:1883-1891.
42. Cauley JA, Lui LY, Stone KL, Hillier TA, Zmuda JM, Hochberg M, Beck TJ,
Ensrud KE: Longitudinal study of changes in hip bone mineral density in
Caucasian and African-American women. J Am Geriatr Soc 2005,
53:183-189.
43. Aloia JF: African Americans, 25-hydroxyvitamin D, and osteoporosis: a
paradox. Am J Clin Nutr 2008, 88:545S-550S.
44. Kohler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LA, Eheman C, Jemal A,
Anderson RN, Ajani UA, Edwards BK: Annual report to the nation on the
status of cancer, 1975-2007, featuring tumors of the brain and other
nervous system. J Natl Cancer Inst 2011, 103:714-736.
45. McTiernan A, Tworoger SS, Ulrich CM, Yasui Y, Irwin ML, Rajan KB,
Sorensen B, Rudolph RE, Bowen D, Stanczyk FZ, Potter JD, Schwartz RS:
Effect of exercise on serum estrogens in postmenopausal women: a 12-
month randomized clinical trial. Cancer Res 2004, 64:2923-2928.
46. McTiernan A, Tworoger SS, Rajan KB, Yasui Y, Sorenson B, Ulrich CM,
Chubak J, Stanczyk FZ, Bowen D, Irwin ML, Rudolph RE, Potter JD,
Schwartz RS: Effect of exercise on serum androgens in postmenopausal
women: a 12-month randomized clinical trial. Cancer Epidemiol Biomarkers
Prev 2004, 13:1099-1105.
47. Monninkhof EM, Velthuis MJ, Peeters PH, Twisk JW, Schuit AJ: Effect of
exercise on postmenopausal sex hormone levels and role of body fat: a
randomized controlled trial. J Clin Oncol 2009, 27:4492-4499.
48. Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PH, Biessy C, Dossus L,
Lukanova A, Bingham S, Khaw KT, Allen NE, Bueno-de-Mesquita HB, van
Gils CH, Grobbee D, Boeing H, Lahmann PH, Nagel G, Chang-Claude J,
Clavel-Chapelon F, Fournier A, Thiebaut A, Gonzalez CA, Quiros JR,
Tormo MJ, Ardanaz E, Amiano P, Krogh V, Palli D, Panico S, Tumino R, et al:
Postmenopausal serum androgens, oestrogens and breast cancer risk:
the European prospective investigation into cancer and nutrition. Endocr
Relat Cancer 2005, 12:1071-1082.
49. James RE, Lukanova A, Dossus L, Becker S, Rinaldi S, Tjonneland A, Olsen A,
Overvad K, Mesrine S, Engel P, Clavel-Chapelon F, Chang-Claude J,
Vrieling A, Boeing H, Schutze M, Trichopoulou A, Lagiou P, Trichopoulos D,
Palli D, Krogh V, Panico S, Tumino R, Sacerdote C, Rodriguez L, Buckland G,
Sanchez MJ, Amiano P, Ardanaz E, Bueno-de-Mesquita B, Ros MM, et al:
Postmenopausal serum sex steroids and risk of hormone receptor-
positive and -negative breast cancer: a nested case-control study. Cancer
Prev Res (Phila) 2011, 4:1626-1635.
50. Zeleniuch-Jacquotte A, Gu Y, Shore RE, Koenig KL, Arslan AA, Kato I,
Rinaldi S, Kaaks R, Toniolo P: Postmenopausal levels of sex hormones and
risk of breast carcinoma in situ: results of a prospective study. Int J
Cancer 2005, 114:323-327.
51. Zeleniuch-Jacquotte A, Afanasyeva Y, Kaaks R, Rinaldi S, Scarmo S, Liu M,
Arslan AA, Toniolo P, Shore RE, Koenig KL: Premenopausal serum
androgens and breast cancer risk: a nested case-control study. Breast
Cancer Res 2012, 14:R32.
52. Woolcott CG, Shvetsov YB, Stanczyk FZ, Wilkens LR, White KK, Caberto C,
Henderson BE, Le ML, Kolonel LN, Goodman MT: Plasma sex hormone
concentrations and breast cancer risk in an ethnically diverse population
of postmenopausal women: the Multiethnic Cohort Study. Endocr Relat
Cancer 2010, 17:125-134.
53. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE: Endogenous estrogen,
androgen, and progesterone concentrations and breast cancer risk
among postmenopausal women. J Natl Cancer Inst 2004, 96:1856-1865.
54. Bianchini F, Kaaks R, Vainio H: Overweight, obesity, and cancer risk. Lancet
Oncol 2002, 3:565-574.
55. Kuller LH, Matthews KA, Meilahn EN: Estrogens and women’s health:
interrelation of coronary heart disease, breast cancer and osteoporosis. J
Steroid Biochem Mol Biol 2000, 74:297-309.
56. Friedenreich CM, Orenstein MR: Physical activity and cancer prevention:
etiologic evidence and biological mechanisms. J Nutr 2002,
132:3456S-3464S.
doi:10.1186/bcr3346
Cite this article as: Stolzenberg-Solomon et al.: Sex hormone changes
during weight loss and maintenance in overweight and obese
postmenopausal African-American and non-African-American women.
Breast Cancer Research 2012 14:R141.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Stolzenberg-Solomon et al. Breast Cancer Research 2012, 14:R141
http://breast-cancer-research.com/content/14/5/R141
Page 11 of 11
